Education
About Us
Working with TipRanks
Follow Us
Nanobiotix SA (GB:0QAV)
LSE:0QAV
0QAV Stock Chart & Stats
€18.74
-€0.07(-2.36%)
At close: 4:00 PM EST
€18.74
-€0.07(-2.36%)
Day’s Range― - ―
52-Week Range€2.68 - €25.55
Previous CloseN/A
Volume19.00
Average Volume (3M)47.85K
Market Cap
€908.69M
Enterprise Value€218.02M
Total Cash (Recent Filing)€28.82M
Total Debt (Recent Filing)€51.24M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Apr 28, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,401,120
10 Day Avg. Volume62,181
30 Day Avg. Volume47,854
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-2.17
Price to Sales (P/S)-12.30
P/FCF Ratio-7.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€23.00Price Target Upside22.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentJNJ recently initiated a new Phase 1b study to evaluate JNJ-1900 in combination with chemotherapy, suggesting growing interest to extend the market opportunity of the drug.
Financial StrategyThe company has secured a non-dilutive financing arrangement with HealthCare Royalty for up to $71M, extending their cash runway into early 2028.
Partnership And ValidationTwo large partners, JNJ and HCRx, have provided third-party validation to JNJ-1900, signaling confidence in the asset and providing financing in a non-dilutive way.
Bears Say
Nanobiotix News
0QAV FAQ
What was Nanobiotix SA’s price range in the past 12 months?
Nanobiotix SA lowest share price was €2.68 and its highest was €25.55 in the past 12 months.
What is Nanobiotix SA’s market cap?
Nanobiotix SA’s market cap is €908.69M.
When is Nanobiotix SA’s upcoming earnings report date?
Nanobiotix SA’s upcoming earnings report date is Apr 28, 2026 which is in 128 days.
How were Nanobiotix SA’s earnings last quarter?
Currently, no data Available
Is Nanobiotix SA overvalued?
According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued.
Does Nanobiotix SA pay dividends?
Nanobiotix SA pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on Nanobiotix SA dividends here
What is Nanobiotix SA’s EPS estimate?
Nanobiotix SA’s EPS estimate is <0.01.
How many shares outstanding does Nanobiotix SA have?
Nanobiotix SA has 48,401,120 shares outstanding.
What happened to Nanobiotix SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix SA?
Currently, no hedge funds are holding shares in GB:0QAV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanobiotix SA
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
0QAV Stock 12 Month Forecast
Average Price Target
€23.00
▲(22.73% Upside)
Technical Analysis
Genfit
―
Innate Pharma SA
―
Abivax SA
―
DBV Technologies
―
OSE Immunotherapeutics SA
―
Options Prices
Currently, No data available
---